Efficacy of sacubitril/valsartan in the treatment of hypertension complicated by heart failure with reduced ejection fraction
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
目的 探讨沙库巴曲缬沙坦对高血压合并射血分数降低心力衰竭(HFrEF)的临床疗效与安全性。 方法 随机对照研究。抽取2022年1月至2022年12月联勤保障部队第九八八医院收治的98例高血压合并HFrEF患者，以随机数字表法分为对照组与研究组，每组49例。对照组采用缬沙坦胶囊联合常规治疗，研究组采用沙库巴曲缬沙坦片联合常规治疗。比较两组患者收缩压(SBP)、舒张压(DBP)、平均动脉压(MAP)、左心室射血分数(LVEF)、氨基末端脑钠肽前体(NT－proBNP)、6 min步行距离、治疗有效率及不良反应发生率。 结果 治疗后，两组患者SBP、DBP、MAP值均明显下降，且研究组低于对照组(P<0.05)；治疗12周后，两组LVEF、NT－proBNP、6 min步行距离均显著改善，且研究组LVEF、6 min步行距离优于对照组，NT－proBNP水平低于对照组(P<0.05)。研究组治疗总有效率(93.88%，46/49)高于对照组(79.59%，39/49)，P<0.05。两组患者不良反应发生率比较差异未见统计学意义(P>0.05)。治疗后12周，研究组因心力衰竭再入院率(4.08%，2/49)低于对照组(8.16%，4/49)，但差异未见统计学意义(P>0.05)。 结论 沙库巴曲缬沙坦是一种有效且安全的治疗高血压合并HFrEF的药物，可显著改善患者的血压和心功能。 Objective To investigate the clinical efficacy and safety of sacubitril/valsartan in the treatment of hypertension complicated by heart failure with reduced ejection fraction (HFrEF). Methods A total of 98 patients with hypertension complicated by HFrEF admitted to No. 990 Hospital of the Joint Logistic Support Force from January 2022 to December 2022 were selected for the randomized controlled study. And they were divided into control group and study group by random number table method, with 49 cases in each group. The control group received conventional treatment combined with valsartan capsules, and the study group received sacubitril/valsartan tablets combined with conventional treatment. Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), left ventricular ejection fraction (LVEF), N-terminal pro B-type natriuretic peptide (NT-proBNP), 6-minute walking distance, effective rate and incidence of adverse reactions were compared between the two groups. Results After treatment, the SBP, DBP and MAP in the two groups decreased notably, and these indicators in the study group were lower than those in the control group (P<0.05). After 12 weeks of treatment, LVEF, NT-proBNP and 6-minute walking distance in both groups were significantly improved (P<0.05) moreover, the LVEF and 6-minute walking distance in the study group were better after 12 weeks of treatment, while the NT-proBNP level in the study group was lower compared with the control group (P<0.05). The total effective rate in the study group (93.88%, 46/49) was higher than that in the control group (79.59%, 39/49),P<0.05. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The rate of re-hospitalization for heart failure in the study group (4.08%, 2/49) was lower than that in the control group (8.16%, 4/49), but the difference was not significant (P>0.05). Conclusions Sacubitril/valsartan is an effective and safe drug in the treatment of hypertension complicated by HFrEF, which can significantly improve blood pressure and cardiac function.
Objective To investigate the clinical efficacy and safety of sacubitril/valsartan in the treatment of hypertension complicated by heart failure with reduced ejection fraction (HFrEF). Methods A total of 98 patients with hypertension complicated by HFrEF admitted to No. 990 Hospital of the Joint Logistic Support Force from January 2022 to December 2022 were selected for the randomized controlled study. And they were divided into control group and study group by random number table method, with 49 cases in each group. The control group received conventional treatment combined with valsartan capsules, and the study group received sacubitril/valsartan tablets combined with conventional treatment. Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), left ventricular ejection fraction (LVEF), N-terminal pro B-type natriuretic peptide (NT-proBNP), 6-minute walking distance, effective rate and incidence of adverse reactions were compared between the two groups. Results After treatment, the SBP, DBP and MAP in the two groups decreased notably, and these indicators in the study group were lower than those in the control group (P<0.05). After 12 weeks of treatment, LVEF, NT-proBNP and 6-minute walking distance in both groups were significantly improved (P<0.05) moreover, the LVEF and 6-minute walking distance in the study group were better after 12 weeks of treatment, while the NT-proBNP level in the study group was lower compared with the control group (P<0.05). The total effective rate in the study group (93.88%, 46/49) was higher than that in the control group (79.59%, 39/49),P<0.05. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The rate of re-hospitalization for heart failure in the study group (4.08%, 2/49) was lower than that in the control group (8.16%, 4/49), but the difference was not significant (P>0.05). Conclusions Sacubitril/valsartan is an effective and safe drug in the treatment of hypertension complicated by HFrEF, which can significantly improve blood pressure and cardiac function.
HypertensionSacubitril valsartanHeart failure with reduced ejection fractionEffect of treatment
万方数据
